Latest News and Press Releases

Data from the ongoing Phase 2 of EO4010 demonstrate tumor target specific immune responses and objective tumor responses, including in liver mets, in patients with previously treated microsatellite...

46% objective response rate, with 15% complete responses and 31% partial responses in patients with early-stage follicular lymphoma reported at the ASH 2024 meeting.Well-tolerated treatment with no...

Two poster presentations to feature novel data from the Phase 1/2 SIDNEY trial of EO2463 in indolent Non-Hodgkin Lymphoma (iNHL), highlighting initial data from Cohort 2 as monotherapy in a...

PARIS, May 30, 2024 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its...

-  Beneficial clinical responses observed with EO2463 monotherapy already at 6 weeks and complete response rate of 78% in patients treated with EO2463 upon addition of lenalidomide ± rituximab - ...

PARIS, April 25, 2024 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its...

EO2401, a pioneering OncoMimics™ peptide-based immunotherapy, has demonstrated rapid activation and significant expansion of existing effector memory T cells against tumor-associated driver antigens...

PARIS, March 06, 2024 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its...

PARIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on...

Positive data from the ROSALIE Phase 1/2 trial presented at 2023 SNO Annual Meeting Median survival of 14.5 months and 18-months survival rate of 43.1% in a 26-patient cohort where EO2401 was...